CHRIS AMOS to Tumor Suppressor Proteins
This is a "connection" page, showing publications CHRIS AMOS has written about Tumor Suppressor Proteins.
Connection Strength
0.263
-
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann Surg Oncol. 2009 Feb; 16(2):431-9.
Score: 0.060
-
DLG5 variants contribute to Crohn disease risk in a Canadian population. Hum Mutat. 2006 Apr; 27(4):353-8.
Score: 0.050
-
ATM polymorphism and hereditary nonpolyposis colorectal cancer (HNPCC) age of onset (United States). Cancer Causes Control. 2005 Aug; 16(6):749-53.
Score: 0.048
-
The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood. 2004 Mar 01; 103(5):1937-40.
Score: 0.042
-
The genomic landscape of familial glioma. Sci Adv. 2023 04 28; 9(17):eade2675.
Score: 0.041
-
p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 2004 Oct 01; 64(19):6863-6.
Score: 0.011
-
Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2004 Oct; 25(10):1911-6.
Score: 0.011